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We have developed a system for expression and puri-
fication of wild-type human T-cell leukemia virus type 1
(HTLV-1) proteinase to attain sufficient quantities for
structural, kinetic, and biophysical investigations. How-
ever, similar to the human immunodeficiency virus type
1 (HIV-1) proteinase, HTLV-1 proteinase also undergoes
autoproteolysis rapidly upon renaturation to produce
two products. The site of this autoproteolytic cleavage
was mapped, and a resistant HTLV-1 proteinase con-
struct (L40I) as well as another construct, wherein the
two cysteine residues were exchanged to alanines, were
expressed and purified. Oligopeptide substrates repre-
senting the naturally occurring cleavage sites in HTLV-1
were good substrates of the HTLV-1 proteinase. The ki-
netic parameters kcat and Km were nearly identical for
all the three enzymes. Although three of four peptides
representing HTLV-1 proteinase cleavage sites were
fairly good substrates of HIV-1 proteinase, only two of
nine peptides representing HIV-1 proteinase cleavage
sites were hydrolyzed by the HTLV-1 proteinase, sug-
gesting substantial differences in the specificity of the
two enzymes. The large difference in the specificity of
the two enzymes was also demonstrated by inhibition
studies. Of the several inhibitors of HIV-1 or other ret-
roviral proteinases that were tested on HTLV-1 protein-
ase, only two inhibit the enzyme with a Ki lower than 100
nM.
The human T-cell leukemia virus type 1 (HTLV-1)1 is a
retrovirus that has been etiologically associated with human
adult T-cell leukemia (1, 2), HTLV-1-associated myelopathy,
tropical spastic paraparesis (3, 4), and a number of other
chronic diseases (5). Although it has not been shown to be
directly linked to the development of leukemia, several recent
studies indicate that viral replication is critical for the devel-
opment of HTLV-1-associated myelopathy. Initial studies
have reported the treatment of this syndrome using 59-
azidothymidine (6).
All replication-competent retroviruses including HIV and
HTLV-1 code for an aspartic proteinase (PR). Unlike HIV-1,
HTLV-1 PR is coded through a mechanism of expression in
separate gag-pro and gag-pro-pol open reading frames (7). The
level of expression of the Gag and Gag-Pro polyproteins in
HTLV-1 is comparable with that of Gag and Gag-Pol polypro-
teins in HIV-1. The function of the mature 125-amino acid-long
HTLV-1 PR is crucial for virion replication (for a review, see
Ref. 8). The HIV-1 PR proved to be a promising target of
antiretroviral therapy of AIDS, and various PR inhibitors are
now in clinical use (for a review, see Ref. 9).
As in the case of treatment of patients with reverse tran-
scriptase inhibitors, selection of viral variants that are resist-
ant to inhibitors of PR also develops rapidly (9). Some of the
amino acid changes in the HIV-1 PR that are responsible for
drug resistance are found in equivalent positions of other ret-
roviral proteinases, including HTLV-1 (see Fig. 1). A compar-
ative study of various retroviral proteinases is expected to
reveal the common features of their specificity. These studies
will aid in the rational design of inhibitors effective against
different retroviral proteinases, which may reduce the fre-
quency of occurrence of drug-resistant mutants. In this respect,
many inhibitors designed against HIV-1 PR have much re-
duced potency against the closely related HIV-2 PR (10) as well
as against the PR of lentiviral equine infectious anemia virus
(11). Furthermore, a recent study demonstrated that all four
HIV-1 PR inhibitors currently used in therapy failed to block
HTLV-1 Gag processing in vitro (12).
Although several studies report expression of HTLV-1 PR in
Escherichia coli (13–17) as well as its chemical synthesis (18),
its biochemical and kinetic properties and specificity have not
been well described. This can be attributed to the difficulty in
protein purification and to the autoproteolysis that is known to
occur with native retroviral proteinases (19, 20). Peptides rep-
resenting some of the natural cleavage sites of HIV-1 are hy-
drolyzed by HTLV-1 PR (16, 18), although no kinetic parame-
ters were reported for these peptides.
The crystal structures of HIV-1 and several other retroviral
proteinases have been determined (21–23). However, to date no
structural information is available for the HTLV-1 protease.
Furthermore, insight into the mechanism of autocatalytic mat-
uration of the mature PR from the precursor is limited to HIV-1
(24, 25). Here we report the high level expression in E. coli and
rapid purification of wild type and autoproteolysis-resistant
HTLV-1 proteinases. The specificities of these two enzymes
were compared utilizing synthetic peptides that correspond to
known Gag and Pol cleavage sites of HIV-1 and HTLV-1. Sev-
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eral potent inhibitors of HIV-1 PR and other retroviral protein-
ases have been assessed for their inhibition of the HTLV-1 PR.
We also report the effect of substituting the two cysteine resi-
dues in HTLV-1 PR and define a chromogenic substrate for
assaying this enzyme.
MATERIALS AND METHODS
Cloning, Expression, and Site-directed Mutagenesis of the HTLV-1
Proteinase—The PR coding region of the SacI fragment of an infec-
tious HTLV-1 clone, pCS-HTLV-I (26), derived by polymerase chain
reaction amplification was cloned at the NdeI and BamHI sites of
pET-11a vector (Novagen, WI). Mutagenesis of the Leu40 to Ile was
performed by using the overlap extension method (27). The C90A and
C109A mutations were introduced into the L40I-mutated HTLV-I PR
using the Quick-Change mutagenesis protocol (Stratagene, CA).
Triple mutant L40I,C90A,C109A PR was prepared by using the
L40I,C109A double mutant as the template.
Cells bearing the construct for the expression of the wild-type
HTLV-1 PR and its mutants were grown in Luria-Bertani medium
supplemented with 1% glucose at 37 °C, 30% pO2, pH 7.0, in a 3-l Braun
model MD fermentor. When the cell suspension reached an absorbance
of 0.5–0.6 at 600 nm, protein expression was induced by the addition of
2 mM isopropyl b-D-thiogalactopyranoside for 3–4 h. Cells (4 g) were
suspended in 20 volumes of buffer A (50 mM Tris-HCl, pH 8.2, 1 mM
DTT, 1 mM EDTA) containing 100 mg/ml lysozyme and lysed by soni-
cation. The insoluble recombinant protein (inclusion bodies) was
washed twice by resuspension in buffer A containing 1 M urea and 1%
Triton X-100 and pelleted by centrifugation at 20,000 3 g for 30 min.
The final pellet was solubilized in 50 mM Tris-HCl, pH 8.0, 7.5 M
guanidine HCl, 5 mM DTT, and 5 mM EDTA and applied to a Superdex
75 column (HiLoad 26 3 60, Amersham Pharmacia Biotech, NJ) equil-
ibrated in 50 mM Tris-HCl, pH 7.5, 4 M guanidine HCl, 5 mM EDTA, and
5 mM DTT at a flow rate of 3 ml/min. Peak fractions were further
purified by reverse-phase HPLC on POROS RII resin (PerSeptive Bio-
systems, MA). HPLC fractions were combined, and aliquots were dried,
assayed for protein content as described previously (28), and subjected
to mass spectroscopic and N-terminal sequence analyses.
Protein Folding—The HPLC-purified protein fractions were dialyzed
in large excess of 25 mM formic acid, pH 2.8, and subsequently into 50
mM sodium acetate buffer, pH 5.0, 1 mM, DTT, 1 mM EDTA. For kinetic
studies, a portion of the protein in 25 mM formic acid was quenched with
at least 100-fold excess of 20 mM PIPES buffer, pH 7.0, containing 150
mM NaCl, 10% glycerol, 1 mM EDTA, 2 mM DTT, and 0.5% Nonidet
P-40.
Oligopeptide Synthesis and Characterization—Oligopeptides were
synthesized by standard tert-butoxycarbonyl or 9-fluorenylmethyloxy-
carbonyl chemistry on a model 430A automated peptide synthesizer
(Applied Biosystems, Inc.) or a semiautomatic Vega peptide synthesizer
(Vega-Fox Biochemicals). All peptides were synthesized with C-termi-
nal amides. Amino acid composition of the peptides was determined
with a Beckman 6300 amino acid analyzer. Stock solutions and dilu-
tions were made in distilled water (or in 10 mM DTT for peptides
containing Cys or Met residues), and the peptide concentrations were
determined by amino acid analysis.
Proteinase Inhibitors—Substrate-based inhibitors of HIV-1 PR as-
sayed as inhibitors of HTLV-1 PR were Ro-31-8959 (29), DMP 323 (30),
UK-88,897 (31), KH 164 (32), and Compound 3 (33). Pepstatin A was
obtained from Sigma, and reduced peptide bond inhibitor (N-1460) was
purchased from Bachem BioScience Inc., King of Prussia, PA. Dr. Ivo
Bla´ha (Ferring Leciva, Prague) prepared the statine- and phenylsta-
tine-containing peptide inhibitors.
Enzyme Assay with Oligopeptide Substrates—Purified HIV-1 PR was
prepared as described previously (34).2 Active-site titration for the
HIV-1 PR was performed with Compound 3 (33). The enzyme concen-
trations for HTLV-1 PR preparations were determined by amino acid
analysis of the stock solutions, and kcat values were calculated by
assuming 100% activity for the PR dimers. The PR assays were initi-
ated by mixing 5 ml of HTLV-1 or HIV-1 PR (8–140 nM), 10 ml of 23
incubation buffer (0.5 M potassium phosphate buffer, pH 5.6, containing
10% glycerol, 2 mM EDTA, 10 mM DTT, 4 M NaCl), and 5 ml of 0.01 to
0.40 mM substrate. The range of substrate concentration was selected
depending on the approximate Km values. The reaction mixture was
incubated at 37 °C for 1 h and terminated by the addition of guanidine
HCl to give a final concentration of 6 M. The solution was acidified by
the addition of trifluoroacetic acid, and an aliquot was injected onto a
Nova-Pak C18 reversed-phase chromatography column (3.9 3 150 mm,
Waters Associates, Inc.) using an automatic injector. Substrates and
the cleavage products were separated using an increasing water-aceto-
nitrile gradient (0–100%) in the presence of 0.05% trifluoroacetic acid.
Cleavage products were identified by amino acid analysis. Kinetic pa-
rameters were determined by fitting the data obtained at less than 20%
substrate hydrolysis to the Michaelis-Menten equation by using the
Fig. P program (Fig. P Software Corp.). To assay the inhibitors, the
volume of substrate KTKVL2VVQPK was reduced to 4.8 ml (0.25 mM
final concentration), and 0.2 ml of inhibitor (in water or in Me2SO) was
added. Inhibitors were initially tested at 10 mM or higher concentration.
Me2SO was also added at the same concentration to the appropriate
control experiments. When inhibition was observed in initial testing, Ki
values were determined according to Dixon (35). A competitive mode of
inhibition was observed, and the standard error for Ki values was
estimated to be below 20%.
RESULTS AND DISCUSSION
Expression and Purification of HTLV-1 Proteinase—The
375-base pair coding region derived from an infectious clone
of HTLV-1 by polymerase chain reaction was cloned into
pET-11a vector and expressed in E. coli. Fig. 2 (lanes 1 and 2)
shows the analysis of the total cell lysate before and after
isopropyl b-D-thiogalactopyranoside induction. Two products
were observed, the larger molecular weight product corre-
sponding to the full-length mature PR and a smaller product
with an apparent size of roughly 7 kDa. The latter product
was expected to be the result of self-degradation (autoprote-
olysis) of the mature PR rather than by premature termina-
tion during expression.
As in the case of HIV-1 PR (28, 36), expression of HTLV-1 PR
results in its accumulation in the form of inclusion bodies.
Lanes 3, 4, and 5 show the supernatant upon lysis of cells and
the supernatant and the pellet derived after 1 M urea treatment
of the initial insoluble pellet, respectively. A comparison of
lanes 4 and 5 shows that 1 M urea partially solublizes the
full-length PR but not the truncated protein. The insoluble
fraction after 1 M urea treatment of the inclusion bodies (see
lane 5) was solubilized in guanidine hydrochloride and sub-
jected to size-exclusion chromatography under denaturing con-
ditions. The peak fractions of both the full-length PR and the
truncated protein were further subjected to reverse-phase
HPLC chromatography. The two proteins that were .98% pure
2 J. M. Louis, unpublished data.
FIG. 1. Sequence comparison of
HIV-1 and HTLV-1 proteinases. The
three conserved regions of proteinases of
HIV-1HXB2 and HTLV-1 (from clone CS95)
are shown in bold. Residues of HTLV-1
PR that are found in equivalent positions
of drug-resistant variants of HIV-1 pro-
teinases are underlined. Additionally,
three frequently occurring drug-resistant
mutations in HIV-1, G48V, A71V, and
V82F, are represented by residues L, L,
and W in equivalent positions in HTLV-1
PR.
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were analyzed for their mass and N-terminal sequence. The
full-length mature PR clearly corresponded to the expected
N-terminal sequence and mass (m/z 5 13475). The truncated
protein showed its N-terminal sequence to start with residues
Pro-Ile-Ala-Leu-Phe-Ser-Ser, and the expected mass was close
to the experimental value (m/z 5 9171). From these results, we
confirmed our prediction that the truncated protein is derived
via autoproteolysis between residues Leu-40/Pro-41 of the full-
length mature PR with a sequence spanning amino acids 41
through 125, now termed PR 41–125. The pure full-length
protein was also renatured from 25 mM formic acid into 50 mM
sodium acetate buffer, pH 5.5, 1 mM DTT, 1 mM EDTA, and
0.05% Triton X-100 at a final concentration of 6.7 mM and
subjected to SDS-polyacrylamide gel electrophoresis (Fig. 2,
lane 6). As expected, the full-length PR gave rise to two prod-
ucts, with apparent mobilities corresponding to ;9 and 4.5
kDa. The latter protein is termed PR 1–40. Also, similar to the
HIV-1 PR, autoproteolysis of the HTLV-1 PR proceeds roughly
to about 50%. It is likely that either one or both products inhibit
further autoproteolysis. This site of autoproteolysis in HTLV-1
PR is analogous to a less susceptible site in HIV-1 PR (Leu33-
Glu34). The major cleavage in HIV-1 PR occurs between resi-
dues Leu5 and Trp6 (19). Recently the feline immunodeficiency
virus PR was also shown to undergo autoproteolysis at four
primary sites in its 116-amino acid sequence (20).
Autoproteolysis-resistant HTLV-1 Proteinase—To prevent
autoproteolysis of the mature HTLV-1 PR, the Leu40 residue
was substituted with an Ile. This substitution was chosen be-
cause it has been shown by using synthetic peptides and pro-
teins as substrates that HIV-1 and other retroviral proteinases
cannot process at the C-terminal side of b-branched residues
(37, 38). Furthermore, autoprocessing at an equivalent position
(Leu33) and another position (Leu63) in HIV-1 was effectively
reduced by substituting these residues with Ile without impair-
ing the kcat/Km for several substrates (36). The expression of
the HTLV-1 PR bearing the mutation L40I compared with the
wild-type PR is shown in Fig. 3. Clearly as observed in dupli-
cate clones, there is a single product that accumulates with a
substantially higher yield corresponding to the size of the full-
length PR. 1.6 g (wet weight) of cells derived from 0.4 liters of
culture yields ;19 and 14 mg of PR after size-exclusion and
reversed-phase HPLC chromatography, respectively.
Kinetic Characterization of the Wild-type and L40I HTLV-I
Proteinases—Based on the sequence comparison with HIV-1
PR and homologous molecular modeling,3 the Leu40 residue of
HTLV-1 PR is not expected to interact with the substrate or
inhibitor. Therefore we predicted that substituting this residue
with Ile would not change the kinetic parameters but would
prevent its autolysis as compared with the wild-type enzyme.
To verify this assumption and to characterize the HTLV-1 PR
specificity, kinetic analysis was performed using oligopeptide
substrates. The proteinases were renatured by quenching the
denatured protein in 50 mM formic acid into 100-fold excess of
PIPES buffer at pH 7.0 under conditions similar to those pre-
viously described for refolding HIV-2 and equine infectious
anemia virus proteinases (39). Kinetic data for the wild type
and L40I mutant PR-catalyzed hydrolysis of synthetic sub-
strates are shown in Table I. Both enzymes exhibit nearly
identical kinetic parameters. The nearly identical values of kcat
for the wild-type and mutant enzymes also suggest that under
3 P. Bagossi, G. Zahuczky, and J. Tozser, unpublished results.
FIG. 3. Expression of the stabilized (L40I) HTLV-1 proteinase.
Analyses of total cell lysate prepared from E. coli bearing the construct
for the expression of the stabilized (L40I) HTLV-1 PR after isopropyl
b-D-thiogalactopyranoside induction are shown in 1 lanes. Cell lysates
prepared from the wild type (WT) clone before (2 lane) and after (1
lane) induction are shown as controls. M denoted molecular mass stand-
ards in kDa. Proteins were electrophoresed on 10–20% gradient poly-
acrylamide gels (Novex), and bands were visualized by Coomassie
staining.
FIG. 2. Expression and purification of the wild-type HTLV-1 proteinase and demonstration of its intrinsic autoproteolysis.
Analyses of total cell lysate prepared from E. coli bearing the construct for the expression of the wild-type HTLV-1 PR before and after isopropyl
b-D-thiogalactopyranoside induction are shown in lanes 1 and 2, respectively. Lane 3 shows the soluble supernatant derived after lysis of induced
cells in 50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 10 mM DTT, and 100 mg/ml lysozyme. The insoluble pellet attained from this step was treated with
1 M urea solution in buffer containing 50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 10 mM DTT, 0.5% Nonidet P-40. The soluble supernatant and the
pellet (inclusion bodies) that were derived from this step are shown in lanes 4 and 5, respectively. The inclusion bodies were solubilized, and the
mature PR was purified to homogeneity by size-exclusion followed by reverse-phase HPLC chromatography. The purified PR that was renatured
from 50 mM formic acid into 50 mM sodium acetate buffer, pH 5.5, 1 mM DTT, and 0.05% Triton-100 is shown in lane 6. Proteins were
electrophoresed on 10–20% gradient polyacrylamide gels (Novex, CA), and bands were visualized by Coomassie staining. M denotes molecular
mass standards in kDa. Mature PR and truncated PR 41–125 were confirmed by N-terminal sequencing and mass spectrometry. Arrows indicate
the truncated PR 41–125 before its characterization.
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these refolding and assay conditions there is no significant
autoproteolysis of the wild-type PR. Stabilization of the enzyme
can be attributed to 1) the refolding procedure, which involves
quenching the denatured protein with a large excess of buffer
(pH 7) to a final concentration of 0.1 mM as compared with
dialyzing the protein to pH 5.0 at a higher protein concentra-
tion and 2) presence of Nonidet P-40 and glycerol in the quench
buffer.
Mutation of the Cysteine Residues of the Stabilized HTLV-1
Proteinase—Because one of our major objectives was to produce
quantities of enzyme suitable for structural studies by solution
NMR and x-ray crystallography, we next addressed the role of
the two cysteines (Cys90, Cys109) on enzymatic activity and
specificity of the PR. It was shown that a Cys to Ala substitu-
tion at residue 95 of HIV-1 mature PR greatly reduced the
tendency of the protein to form an intermolecular disulfide
bond (40). Subsequent studies have shown that both the Cys67
and Cys95 residues of HIV-1 can be exchanged to Ala without
significantly affecting the structure and kinetic parameters
(41).2
Constructs bearing either or both of the two cysteines
substituted by Ala were prepared in a L40I HTLV-1 PR
construct as described under “Materials and Methods.” We
chose to compare the triple mutant L40I,C90A,C109A
(termed C2A-PR) with the wild-type PR. C2A-PR was puri-
fied as described before for the wild-type HTLV-1 PR. Fig. 4
shows the enzyme before and after refolding. Clearly the
refolded enzyme was stable up to 24 h at a concentration of
0.6 mM at ambient temperature. The triple mutant was used
to compare the specificity of HTLV-1 and HIV-1 proteinases
on naturally occurring cleavage sites of HTLV-1 Gag-Pol
polyprotein (Table II).
Kinetic Characterization of the Stabilized C2A-PR Mutant
HTLV-1 Proteinase and Comparison of Its Specificity with
HIV-1 Proteinase—To characterize the specificity of C2A-PR,
we first used oligopeptide substrates that represent naturally
occurring cleavage sites in HTLV-1 Gag-Pol polyprotein. Com-
parison of the kinetic parameters using C2A-PR (Table II) to
those obtained with wild-type and L40I mutant enzymes (Table
I) suggest that substitution of the Cys residues to Ala does not
alter its catalytic activity. Three of the four peptides tested
were excellent substrates of HTLV-1 PR, with catalytic con-
stants comparable with the best naturally occurring HIV-1
cleavage site substrates with HIV-1 PR (42). Thus HTLV PR is
an enzyme with high specific activity, similar to HIV-1 PR but
unlike avian myeloblastosis virus PR, which has much lower
kcat for its specific substrates. This interpretation is consistent
with the mechanisms that regulate the level of expression of
the Gag and Gag-Pol products. HIV-1 and HTLV-1, wherein
the PR is coded in a Pol open reading frame at ;10-fold lower
level than Gag proteins, have higher specific activity for the PR
as compared with avian myeloblastosis virus PR, which is
coded in a Gag open reading frame. Another interesting simi-
larity with the HIV-1 and HTLV-1 proteinases is that among
the least efficient sites for hydrolysis is the one that yields the
free N terminus of PR (42). Studies with an analog of the HIV-1
PR precursor indicate that the cleavage at the N terminus of
the PR occurs intramolecularly, concomitant with a large in-
crease in enzymatic activity, and this cleavage has been sug-
gested to be the rate-limiting step in the maturation cascade of
Gag-Pol polyprotein (24, 43). When HTLV-1 cleavage site sub-
strates were used as substrates for HIV-1 PR (Table II), three
of four peptides were found to be hydrolyzed. The kinetic pa-
rameters of HIV-1 PR-catalyzed hydrolysis of these HTLV-1
substrates were in the same range as those for substrates that
correspond to analogous sites in HIV-1 (42). On the other hand,
only two of the nine HIV-1 cleavage site substrates were
cleaved by the HTLV-1 PR (Table III) but with substantially
lower values of kcat/Km than those obtained with HTLV-1
substrates.
The lack of cleavage of HIV-1 Gag substrates by HTLV-1 PR
is in good agreement with previous findings that HTLV-1 PR
was not able to process HIV-1 Gag precursor in a vaccinia virus
expression system (44). In the same expression system, HIV-1
FIG. 4. Analysis by SDS-polyacrylamide gel electrophoresis of
the triply mutated (L40I, C90A, C109A, or C2A-PR) HTLV-1 PR
before and after protein folding. Triply mutated HTLV-1 PR was
purified similar to the conditions described for the wild-type enzyme.
Protein was renatured similar to conditions described under “Materials
and Methods” and concentrated to 0.6 mM. A fraction of the enzyme
before and after refolding that was subjected to 10–20% gradient SDS-
polyacrylamide gel electrophoresis is shown in lanes 1 and 2, respec-
tively. M denoted molecular mass standards in kDa.
TABLE I
Kinetic parameters for hydrolysis of naturally occurring HTLV-1 cleavage site peptides by wild-type and L40I mutant HTLV-1 proteinases
wt, wild type.
Cleavage
site Substrate sequence Enzyme Km kcat kcat/Km
mM s21 mM21s21
MA/CA APQVL2PVMHP HTLV-1 (wt) 0.115 6 0.018 8.67 6 0.60 75.4
HTLV-1 (L40I) 0.098 6 0.020 6.78 6 0.50 69.2
CA/NC KTKVL2VVQPK HTLV-1 (wt) 0.033 6 0.004 5.15 6 0.10 156.1
HTLV-1 (L40I) 0.032 6 0.004 5.18 6 0.12 161.8
TF1/PR DPASIL2PVIP HTLV-1 (wt) 0.230 6 0.035 0.70 6 0.05 3.0
HTLV-1 (L40I) 0.244 6 0.033 0.62 6 0.04 2.5
PR/p3 KGPPVIL2PIQAP HTLV-1 (wt) 0.030 6 0.006 6.91 6 0.39 230.3
HTLV-1 (L40I) 0.034 6 0.005 6.26 6 0.30 184.2
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PR was also not able to process HTLV-1 Gag (44) even though
the peptides representing HTLV-1 Gag cleavage sites were
hydrolyzed by HIV-1 PR in vitro. This result in vivo may at
least partially be because of reduced specificity of this enzyme
toward these sites as compared with HTLV-1 PR.
Hydrolysis of Chromogenic Substrates by HTLV-1 Protein-
ase—To develop a more convenient chromogenic assay, we syn-
thesized and assayed analogs of the HTLV-1 CA/NC cleavage
site substrate that contained a Phe (NO2) substitution in either
the P1 or P19 positions (Table III). Although the substrate with
P19 substitution was an inefficient substrate, the substrate
containing the P1 substitution was hydrolyzed to about 4% the
level of the native substrate. This substrate may serve to
screen for ideal-folding conditions of C2A-PR in simple buffer
systems for structural studies. In good agreement with the lack
of hydrolysis of the HIV-1 CA/p2 peptide by HTLV-1 PR, its
chromogenic derivative, which is a widely used chromogenic
substrate of HIV-1 PR was not hydrolyzed (Table III).
Daenke et al. (16) reported kinetic parameters for peptides
representing naturally occurring cleavage sites of HTLV-1 in
which the P19 residue were substituted by a chromogenic re-
porter, Phe (NO2). They have reported Km and kcat values
within a range of 0.003–0.031 mM and 14–33 s21, respectively.
These Km values are lower than our observed values (0.030–
0.230 mM, see Table I) using entirely natural peptides with no
substitutions whereas the kcat values were substantially
higher, assayed under similar conditions. The difference in Km
values may be because of the introduction of the bulky aromatic
residue in the P19 position. This may also be the reason why the
naturally occurring cleavage site sequences representing the
autocatalytic maturation sites (TF1/PR and PR/p3) in HTLV-1
as compared with the corresponding chromogenic derivatives
do not have substantially higher affinities toward HTLV-1 PR
than the peptides representing other sites, as noted for the
chromogenic derivatives by Daenke et al. (16). The reason for
the differences in the reported kcat values is less obvious. When
we introduced Phe(NO2) group in either the P1 or P19 positions
of the naturally occurring cleavage site sequence, a substantial
decrease in hydrolytic rate was observed instead of the ex-
pected increase (see Table III). Our observations which suggest
that bulky residues at the site of cleavage are unfavorable are
in accordance with the interpretation of Pettit et al. (12) that
lack of inhibition by HIV-1 PR inhibitors on in vitro HTLV-1
Gag processing might be because of the presence of Trp98 in
HTLV-1 rather than Val in equivalent position of HIV-1 reduc-
ing the size of S1 binding pocket. A two-fold increase in NaCl
concentration used in our assay conditions as compared with
that reported (16) does not account for this large difference in
kcat values. The specific activity reported using the chromo-
genic substrate representing the CA/NC site (1 mmol/min/mg;
Ref. 16) suggests a much smaller catalytic rate.
Inhibition of the HTLV-1 Proteinase—Several inhibitors of
HIV-1 PR were assayed as inhibitors of the HTLV-1 PR. DMP
323, KH 164, and Compound 3 have previously been shown to
be potent inhibitors of the HIV-1 PR. Only Compound 3 inhib-
ited HTLV-1 PR with a Ki of 80 nM, whereas the others did not
inhibit up to 10 mM (Table VI). Another potent inhibitor of
HIV-1 PR, Ro-31-8959 was also inactive against HTLV-1 PR
(16). These results also emphasize the large differences in
specificity of the two enzymes. Interestingly, Compound 3 was
also a good inhibitor of HIV-2 PR (45), equine infectious anemia
virus PR (39), murine leukemia virus, and mouse mammary
tumor virus proteinases (46) and, therefore, may serve as a
lead compound for general inhibitors of retroviral proteinases.
However, the most potent inhibitor of the enzyme in our assay
system was a statine-based inhibitor, which was based on the
MA/CA cleavage site sequence with a Ki of 50 nM (Inhibitor 10
in Table IV). Potent, active-site inhibitor of Mason-Pfizer mon-
key virus PR (Inhibitor 9 in Table IV; Ref. 47) and avian
myeloblastosis virus PR (Inhibitor 8 in Table IV; Ref. 50) also
TABLE II
Kinetic parameters for hydrolysis of naturally occurring HTLV-1 cleavage site peptides by C2A-PR and wild-type HIV-1 PR
ND, cleavage products not detected in the assay performed as described under “Materials and Methods” using 0.3 mM substrate and 100 nM
enzyme (kcat is estimated to be smaller than 0.01 s
21).
Cleavage site Substrate sequence Enzyme Km kcat kcat/Km
mM s21 mM21s21
MA/CA APQVL2PVMHP C2A-PR 0.069 6 0.020 5.88 6 0.59 85.2
HIV-1 PR 0.023 6 0.004 0.37 6 0.01 16.1
CA/NC KTKVL2VVQPK C2A-PR 0.051 6 0.005 7.68 6 0.17 150.6
HIV-1 PR 0.182 6 0.033 2.60 6 0.20 14.3
TF1/PR DPASIL2PVIP C2A-PR 0.221 6 0.031 0.84 6 0.05 3.8
HIV-1 PR ND
PR/p3 KGPPVIL2PIQAP C2A-PR 0.041 6 0.010 11.82 6 0.89 288.3
HIV-1 PR 0.025 6 0.002 0.21 6 0.01 8.4
TABLE III
Hydrolysis of oligopeptides representing naturally occurring HIV-1 cleavage sites and chromogenic substrates by the C2A-PR
ND, cleavage products not detected in the assay performed as described under “Materials and Methods” using 0.3 mM substrate and 600 nM
C2A-PR (kcat is estimated to be smaller than 0.002 s
21). F, 4-nitrophenylalanine.
Cleavage site Substrate sequence Km kcat kcat/Km
mM s21 mM21s21
HIV-1 MA/CA VSQNY2PIVQ ND
CA/p2 KARVL2AEAMS ND
p2/NC TATIM2MQRGN ND
NC/p1 ERQAN2FLGKI ND
p1/p6 RPGNF2LQSRP ND
in p6 DKELY2PLTSL .0.5 0.02
TF/PR VSFNF2PQITL ND
PR/reverse transcriptase CTLNF2PISP ND
Reverse transcriptase/IN IRKIL2FLDG 0.283 6 0.038 0.21 6 0.01 8.4
HIV-1 CA/p2 KARVL2FEAM ND
HTLV CA/NC KTKVL2FVQPK .0.3 ,0.01 0.04
HTLV CA/NC KTKVF2VVQPK 0.188 6 0.013 1.23 6 0.04 6.5
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did not inhibit the HTLV-1 PR. N-1460, a low nM peptide
analog inhibitor of HIV-1 PR, and LP-149, inhibitor of HIV-1
and feline immunodeficiency virus proteinases, do not inhibit
HTLV-1 PR up to 10 mM.
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